McKesson (MCK), a leading global healthcare company and North American pharmaceutical distributor, is demonstrating strong momentum, fueled by growth in specialty pharmaceuticals and GLP-1 medications, which contributed nearly $41 billion in FY25 revenue. Despite a Zacks Rank #3 (Hold), MCK holds a robust VGM Score of A and a Momentum Style Score of B, with its shares climbing 9.5% over the past four weeks. Analyst outlook is positive, with six analysts recently raising fiscal 2026 earnings estimates, increasing the consensus to $38.05 per share, alongside an average earnings surprise of +1.5%.
McKesson Corporation (MCK) demonstrates robust operational strength as a leading global healthcare company and pharmaceutical distributor in North America. Key growth drivers include specialty pharmaceuticals, oncology services, and GLP-1 medications, with GLP-1 revenues alone reaching nearly $41 billion in FY25. This highlights a significant and expanding revenue stream for the company. The stock exhibits strong market momentum, with shares appreciating 9.5% over the past four weeks. This performance is supported by a top-tier Zacks VGM Score of A and a Momentum Style Score of B, indicating favorable combined value, growth, and momentum characteristics. Analyst sentiment remains positive, evidenced by six analysts revising their fiscal 2026 earnings estimates higher in the last 60 days. The Zacks Consensus Estimate for FY26 has consequently increased by $0.88 to $38.05 per share, complemented by a historical average earnings surprise of +1.5%. Despite a current Zacks Rank #3 (Hold), these upward revisions and strong style scores suggest underlying fundamental strength.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
